Shanghai Junshi Biosciences Co., Ltd announced its 2025 interim financial results, with total revenue reaching approximately RMB1,168 million, a 49% increase from 2024. The company’s core product, TUOYI®, saw domestic sales revenue rise to approximately RMB954 million. Research and development expenses were approximately RMB745 million, a 36% increase from 2024. Loss attributable to owners decreased by approximately 36%. Junshi Biosciences also achieved milestones in drug development, including gaining approval for new indications and expanding international collaborations.
The company focused on addressing unmet medical needs and made progress in developing innovative therapies across various therapeutic areas. Advancements in the pipeline included commercializing four drugs and having over 30 assets in clinical trials. Achievements in drug approvals included TUOYI® for unresectable or metastatic melanoma and MINDEWEI for COVID-19 treatment. External collaborations, such as a distribution and marketing agreement with LEO Pharma, also enhanced the company’s reach in the European market. LEO Pharma has agreed to pay TopAlliance Biosciences an upfront payment of EUR15 million, milestone payments for future approved indications of toripalimab, and a double-digit percentage revenue share on net sales of toripalimab. In June 2025, Junshi Biosciences successfully completed a placing of 41,000,000 H shares, raising approximately HK$1,026 million for drug development and corporate purposes. Junshi Biosciences, founded in 2012, focuses on innovative therapeutics with over 50 drug candidates and approvals in China and international markets. The company is actively involved in developing novel therapies for COVID-19.
Read more at 1. “Tesla announces record-breaking deliveries in the second quarter of 2021.” – CNBC
2. “Apple unveils new iPhone model with upgraded camera features.” – Wall Street Journal
3. “Amazon reports a 44% increase in revenue for the first quarter of 2021.” – Reuters
4. “Facebook faces backlash over data privacy concerns.” – CBS MarketWatch
5. “Google fined $5 billion for antitrust violations by European Union.” – Barchart: Junshi Biosciences Announces 2025 Interim Financial Results